Table 3 Competing risk regression to evaluate the effect of selected covariates on prostate cancer incidence

Cholesterol (mmol/l)

<0.001*

<0.001*

0.01*

 Q1 (2.7 – 5.8)

2.15 (1.44–3.22)

<0.001

2.00 (1.32–3.03)

0.001

2.00 (1.20–3.34)

<0.01

 (5.9 – 6.6)

1.36 (0.88–2.09)

0.17

1.29 (0.83–2.00)

0.26

1.46 (0.86–2.48)

0.16

 Q3 (6.7 – 7.4)

1.42 (0.92–2.21)

0.12

1.36 (0.87–2.12)

0.17

1.55 (0.90–2.66)

0.11

 Q4 (7.5 – 15.4)

1

1

1

Age at inclusion (years)

0.48*

0.40*

0.36*

 < 45

1

1

1

 45–49

0.84 (0.58–1.20)

0.33

0.92 (0.64–1.32)

0.66

0.97 (0.66–1.43)

0.89

 50–54

0.87 (0.60–1.25)

0.45

1.09 (0.73–1.62)

0.67

0.86 (0.54–1.35)

0.51

 55+

0.85 (0.57–1.27)

0.43

1.15 (0.75–1.79)

0.52

0.80 (0.46–1.40)

0.44

Smoking

 Never

1

1

1

 Ever

0.75 (0.56–1.01)

0.06

0.79 (0.59–1.07)

0.12

0.81 (0.58–1.14)

0.22

Physical fitness (kJ/kg)

<0.001*

0.01*

0.12*

 T1 (21.1 – 118.6)

1

1

1

 T2 (118.7 – 161.2)

1.38 (0.96–1.98)

0.08

1.43 (0.98–2.07)

0.06

1.27 (0.82–1.99)

0.29

 T3 (161.3 – 515.9)

1.76 (1.25–2.48)

<0.01

1.68 (1.14–2.47)

0.01

1.43 (0.92–2.22)

0.11

Body mass index (kg/m²)

 <25

1

1

1

 ≥ 25

0.66 (0.49–0.89)

<0.01

0.69 (0.52–0.93)

0.01

0.62 (0.44–0.88)

<0.01

Systolic blood pressure (mmHg)

0.59*

0.55*

0.41*

 Q1 (88 – 118)

1

1

1

 Q2 (120 – 128)

0.85 (0.59–1.23)

0.39

0.89 (0.62–1.28)

0.53

1.00 (0.66–1.51)

0.99

 Q3 (130 – 140)

0.83 (0.57–1.22)

0.35

0.96 (0.65–1.40)

0.83

1.06 (0.68–1.65)

0.79

 Q4 (142 – 220)

0.92 (0.64–1.32)

0.63

1.13 (0.78–1.65)

0.52

1.22 (0.78–1.93)

0.37